Patient Satisfaction with Fentanyl Sublingual Spray in Opioid‐Tolerant Patients with Breakthrough Cancer Pain

By  

PAIN PRACTICE, Vol. 15, Iss. 6, 2015-07 ,pp. : 554-563

John Wiley & Sons Inc

Access to resources Recommend Favorite

Low doses of transdermal fentanyl in opioid-naive patients with cancer pain

By Mercadante Sebastiano   Porzio Gianpiero   Ferrera Patrizia   Aielli Federica   Adile Claudio   Ficorella Corrado  

Current Medical Research and Opinion, Vol. 26, Iss. 12, 2010-12 ,pp. : 2765-2768

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain

By Rauck Richard L.   Tark Marvin   Reyes Eva   Hayes Teresa G.   Bartkowiak Anthony J.   Hassman David   Nalamachu Srinivas   Derrick Rob   Howell Julian  

Current Medical Research and Opinion, Vol. 25, Iss. 12, 2009-12 ,pp. : 2877-2885

Informa Healthcare

Access to resources Recommend Favorite

Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain

By Nalamachu Srinivas   Hassman David   Wallace Mark S.   Dumble Sam   Derrick Rob   Howell Julian  

Current Medical Research and Opinion, Vol. 27, Iss. 3, 2011-03 ,pp. : 519-530

Informa Healthcare

Access to resources Recommend Favorite

Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain

By ÜÜberall Michael A.   Müüller-Schwefe Gerhard H.H.  

Current Medical Research and Opinion, Vol. 27, Iss. 7, 2011-07 ,pp. : 1385-1394

Informa Healthcare

Access to resources Recommend Favorite